SCI Abstract

search
Transcriptomic clustering of chronic lymphocytic leukemia: molecular subtypes based on Bruton’s tyrosine kinase expression levels
Transcriptomic clustering of chronic lymphocytic leukemia: molecular subtypes based on Bruton’s tyrosine kinase expression levels
Historically, CLL prognostication relied on disease burden, reflected in clinical stage. Later, chromosome abnormalities a...
Global disparities in drug-related adverse events of patients with multiple myeloma: a pharmacovigilance study
Global disparities in drug-related adverse events of patients with multiple myeloma: a pharmacovigilance study
Multiple myeloma (MM) is a complex hematological malignancy of clonal plasma cells driven by alterations to the chromosoma...
Integration of clinical outcomes and molecular features in extramedullary disease in multiple myeloma
Integration of clinical outcomes and molecular features in extramedullary disease in multiple myeloma
Multiple myeloma (MM) remains incurable despite novel therapeutics. A major contributor to the development of relapsed/ref...
Synergistic effect of FMS-like tyrosine kinase-3 (FLT3) inhibitors combined with a CDK7 inhibitor in FLT3-ITD-mutated acute myeloid leukemia
Synergistic effect of FMS-like tyrosine kinase-3 (FLT3) inhibitors combined with a CDK7 inhibitor in FLT3-ITD-mutated acute myeloid leukemia
Kiyoi H, Naoe T, Nakano Y, Yokota S, Minami S, Miyawaki S, et al. Prognostic implication of FLT3 and N-RAS gene mutations ...
Multiomic analysis identifies a high-risk subgroup that predicts poor prognosis in t(8;21) acute myeloid leukemia
Multiomic analysis identifies a high-risk subgroup that predicts poor prognosis in t(8;21) acute myeloid leukemia
Begna KH, Xu X, Gangat N, Alkhateeb H, Patnaik MM, Al-Kali A, et al. Core-binding factor acute myeloid leukemia: long-term...
Current status and research directions in acute myeloid leukemia
Current status and research directions in acute myeloid leukemia
The understanding of the molecular pathobiology of acute myeloid leukemia (AML) has spurred the identification of therapeu...
Characterization of MYC Rearrangements in Multiple Myeloma: an Optical Genome Mapping Approach
Characterization of MYC Rearrangements in Multiple Myeloma: an Optical Genome Mapping Approach
Multiple myeloma (MM) is characterized by complex, heterogeneous genetic abnormalities that significa...
Large B-cell lymphomas with CCND1 rearrangement have different immunoglobulin gene breakpoints and genomic profile than mantle cell lymphoma
Large B-cell lymphomas with CCND1 rearrangement have different immunoglobulin gene breakpoints and genomic profile than mantle cell lymphoma
Mantle cell lymphoma (MCL) is genetically characterized by the IG::CCND1 translocation mediated by an aberrant V(D)J rearr...
The triple A (AAA) model globally recapitulates adverse outcomes in essential thrombocythemia
The triple A (AAA) model globally recapitulates adverse outcomes in essential thrombocythemia
Essential thrombocythemia (ET) is a myeloproliferative neoplasm (MPN) whose clinical course is often ...
Unraveling the genomic underpinnings of unbalanced MYC break-apart FISH results using whole genome sequencing analysis
Unraveling the genomic underpinnings of unbalanced MYC break-apart FISH results using whole genome sequencing analysis
Survey of interpretation practices of unbalanced MYC break-apart resultsFifty-four responses were obtained to the survey q...
Lymphopenia confers poorer prognosis in Myelodysplastic Syndromes with very low and low IPSS-M
Lymphopenia confers poorer prognosis in Myelodysplastic Syndromes with very low and low IPSS-M
Myelodysplastic neoplasms (MDS) are hematopoietic stem cell (HSC) disorders arising in the bone marro...
Sociodemographic associations with uptake of novel therapies for acute myeloid leukemia
Sociodemographic associations with uptake of novel therapies for acute myeloid leukemia
Inequitable uptake of novel therapies (NT) in non-cancer settings are known for patients with lower socioeconomic status (...
A MYC-rearrangement is a negative prognostic factor in stage II, but not in stage I diffuse large B-cell lymphoma
A MYC-rearrangement is a negative prognostic factor in stage II, but not in stage I diffuse large B-cell lymphoma
MYC oncogene rearrangements (MYC-R) negatively affect survival in patients with Ann Arbor stage III–IV diffuse large...
Genomic and functional impact of Trp53 inactivation in JAK2V617F myeloproliferative neoplasms
Genomic and functional impact of Trp53 inactivation in JAK2V617F myeloproliferative neoplasms
Classical myeloproliferative neoplasms (MPNs) are characterized by the proliferation of myeloid cells and the risk of tran...
Long-term outcome of children with acute promyelocytic leukemia: a randomized study of oral versus intravenous arsenic by SCCLG-APL group
Long-term outcome of children with acute promyelocytic leukemia: a randomized study of oral versus intravenous arsenic by SCCLG-APL group
Realgar-Indigo naturalis formula (RIF), an oral traditional Chinese medicine mainly containing Realgar (As4S4), is highly ...
Early mortality after chemotherapy as a quality indicator—the leukemia perspective
Wright AA, Zhang B, Keating NL, Weeks JC, Prigerson HG. Associations between palliative chemotherapy and adult cancer pati...
Gene interaction network analysis in multiple myeloma detects complex immune dysregulation associated with shorter survival
Gene interaction network analysis in multiple myeloma detects complex immune dysregulation associated with shorter survival
The plasma cell cancer multiple myeloma (MM) varies significantly in genomic characteristics, response to therapy, and lon...